Pimurutamab (HLX-07) is a glycoengineered humanized IgG1 monoclonal antibody that specifically targets the Epidermal Growth Factor Receptor (EGFR/HER1). By binding to the extracellular domain of EGFR, Pimurutamab blocks ligand (e.g., EGF, TGF-α) binding, inhibiting receptor dimerization and downstream signaling cascades (e.g., RAS/RAF/MEK/ERK). Its optimized glycosylation profile significantly enhances Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) activity. Pimurutamab is developed for treating EGFR-overexpressing solid tumors, such as colorectal cancer and head and neck squamous cell carcinoma, with potentially improved efficacy over cetuximab.